In addition, by inhibiting the proliferation and migration ability of VSMCs, the consequence of phenotypic conversion inhibition of VSMCs, this nano-drug showed the strong therapeutic effect on atherosclerosis treatment, significantly reducing plaque and circulating PCSK9 levels after 8 weeks of treatment. The gene discussed is PCSK9; the disease is atherosclerosis.